Nektar Therapeutics reported a better-than-expected loss in the fourth quarter but lagged analysts’ expectations for revenues. Shares of the biopharmaceutical company dropped almost …
Nektar Therapeutics (NKTR) presented some updated results on Friday, November 9th from the melanoma expansion cohort of Phase II from PIVOT-02 study. The cancer-focused …
By Genia Turanova There’s nothing like cash to show how successful a company has been. When a fledgling enterprise first turns cash-flow positive …
Mizuho’s Difei Yang offers a bullish take on NKTR stock in a week that saw Wall Street running for the hills on the drug maker.
What’s up with Nektar Therapeutics (NASDAQ:NKTR)? Data released over the weekend at the annual meeting of the American Society of Clinical Oncology (ASCO) doesn’t …
To say that expectations had soared to levels of strong enthusiasm on the San-Francisco based biotech firm Nektar Therapeutics (NASDAQ:NKTR) and its lead …
Esperion Therapeutics Inc (NASDAQ:ESPR) and Nektar Therapeutics (NASDAQ:NKTR) are skyrocketing with a fury today on back of major clinical strides forward that have investors …
Nektar Therapeutics (NASDAQ:NKTR) reported its financial results for the second quarter ended June 30, 2015. Cash and investments in marketable securities at June 30, …
Nektar Therapeutics (NASDAQ:NKTR) reported that partner Baxalta Incorporated, a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved …
Isis Pharmaceuticals It can be very difficult to find companies that are both flying under the radar, and still might have potential for …
